

Treatment Scientific Committee Meeting



IMPAACT

International Maternal Pediatric Adolescent
AIDS Clinical Trials Network

ANNUAL MEETING

2022

1 July 2022

Treatment Scientific Committee Membership

Chair & Vice Chair: Ted Ruel and Mo Archary

At-large Members

LOC Members

NIH Members

Linda Barlow-Mosha	Brookie Best	Carolyn Bolton Moore	Katie McCarthy	Renee Browning
Edmund Capparelli	Diana Clarke	Lee Fairlie	Sharon Nachman	Fadzi Kasambira
Liz Lowenthal	Mark Mirochnick	Jorge Pinto	Veronica Toone	Ellen Townley
Andy Wiznia			Michael Whitton	Dwight Yin

SBS Core

CAB Members

LC Member

SDMC Members

Rivet Amico	Aisha Gava	Helty Adisetiyo	Sean Brummel
Rachel Kidman	Thabo Makete		Mae Cababasay
			Barb Heckman

3

Objectives for today's session

The road is now ready:

- We have been waiting for long-acting injectables for several years
- New dosing and approvals in pediatric populations
- Expanding access globally!

What happens now?

- It is time to roll out LA CAB RPV in real life settings
- Real world \neq clinical trials, but ...
- What can we learn from delivery in the trials?
- What can we learn from the first rollouts to adults in clinical settings?
- What have learned from the different perspectives of families, youth, and providers?

What next?

- ***What new information do we still need?***
- ***How and when will we get dosing in younger children and pregnancy?***



4

AGENDA

Start Time	Topic	Presenter
9:00	Welcome	Ted Ruel & Mo Archary
9:05	Update from IMPAACT 2017/MOCHA <i>Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents</i>	
	Update on Safety and PK Findings from IMPAACT 2017/MOCHA	Carolyn Bolton & Aditya Gaur
	Adolescent and Parent Experiences with Long-Acting Injectables in the MOCHA Study	Jennifer Chapman
9:25	Introduction to IMPAACT 2036/CRAYON <i>Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age</i>	Mo Archary

AGENDA (continued)

9:30	Introduction to IMPAACT 2040/CREATE <i>Phase I/II Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Virally Suppressed People with HIV-1 during Pregnancy and Postpartum</i>	Rachel Scott & Adrie Bekker
9:35	Lessons Learned from the Roll-Out of LA CAB-RPV	Roy M. Gulick
9:55	Community Perspectives on LA CAB-RPV	Thabo Makete & Aisha Nakitto
10:05	Panel Discussion	All presenters
10:25	Wrap Up	Ted Ruel & Mo Archary
10:30 AM	Adjourn	



For virtual attendees:

Any questions should be sent
via Q&A.



**All virtual attendees will be
muted during the training.**

Please raise your hand if you
would like to speak during this
training.